Related Experiment Video
Updated: May 23, 2026
08:16
An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
Published on: July 7, 2017
Targeting IL-8 in colorectal cancer
1University of Southern California, Keck School of Medicine, Norris Comprehensive Cancer Center, Division of Medical Oncology, Sharon A. Carpenter Laboratory , 1441 Eastlake Ave, Suite3456, Los Angeles, CA 90089 , USA +323 865 3955 ; +1 323 865 0061 ; lenz@usc.edu.
Expert Opinion on Therapeutic Targets
|April 13, 2012
Summary
Interleukin-8 (IL-8) and its receptor CXCR2 are key regulators in colorectal cancer progression. Targeting IL-8/CXCR2 signaling may offer novel therapeutic strategies against this malignancy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Colorectal cancer (CRC) is a leading cause of cancer death.
- Chemokines, like IL-8, and their receptors (e.g., CXCR2) are increasingly recognized as critical regulators and therapeutic targets in CRC.
- IL-8/CXCR2 signaling promotes CRC cell migration, invasion, proliferation, and angiogenesis.
Purpose of the Study:
- To review the role of IL-8 and its receptors in colorectal cancer.
- To update on preclinical models and translational relevance of targeting IL-8/CXCR2 in CRC.
- To evaluate the effects of suppressing IL-8 signaling on tumor progression.
Main Methods:
- Review of existing literature on IL-8 and CXCR2 in colorectal cancer.
- Characterization of IL-8/CXCR2 expression in colon cancer cells.
- Analysis of the IL-8 signaling pathway in CRC cells.
- Evaluation of therapeutic strategies targeting IL-8 or its receptors.
Main Results:
- Increased expression of IL-8 and/or CXCR2 is observed in colon cancer cells.
- IL-8 signaling pathways are active within colorectal cancer cells.
- Targeting IL-8 or CXCR2 strategies are being investigated for CRC treatment.
Conclusions:
- IL-8 and CXCR2 are significant regulatory factors in the tumor microenvironment of colorectal cancers.
- Targeting IL-8/CXCR2 presents a promising therapeutic avenue for colorectal cancer.
- Suppression of IL-8 signaling may exhibit antitumor properties and enhance chemosensitivity.
